Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-IPF
2023-506185-31-00Phase 3Completed
- Sponsor
- Pliant Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Bexotegrast dose-ranging with Placebo (2 arms). Primary endpoint: Change from baseline in absolute FVC (mL) at Week 52. Started Mar 2024; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-506185-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506185-31-00.